Atea Pharmaceuticals Inc AVIR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/30/24 EDT
3.70quote price arrow down-0.01 (-0.27%)
Volume
219,105
52 week range
2.77 - 5.19
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.70
  • 52 Week High5.19
  • 52 Week High Date05/22/23
  • 52 Week Low2.77
  • 52 Week Low Date11/22/23

Key Stats

  • Market Cap311.409M
  • Shares Out84.16M
  • 10 Day Average Volume0.21M
  • Dividend-
  • Dividend Yield-
  • Beta0.19
  • YTD % Change21.31

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.70
  • 52 Week High5.19
  • 52 Week High Date05/22/23
  • 52 Week Low2.77
  • 52 Week Low Date11/22/23
  • Market Cap311.409M
  • Shares Out84.16M
  • 10 Day Average Volume0.21M
  • Dividend-
  • Dividend Yield-
  • Beta0.19
  • YTD % Change21.31

RATIOS/PROFITABILITY

  • EPS (TTM)-1.63
  • P/E (TTM)-2.27
  • Fwd P/E (NTM)-1.34
  • EBITDA (TTM)-120.525M
  • ROE (TTM)-22.74%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)18.55%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Atea Pharmaceuticals Inc

 

Profile

MORE
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir...
Jean-Pierre Sommadossi Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Andrea Corcoran J.D.
Chief Financial Officer, Executive Vice President - Legal , Secretary
Wayne Foster
Executive Vice President, Chief Accounting Officer
Address
225 Franklin Street, Suite 2100
Boston, MA
02110
United States

Top Peers

SYMBOLLASTCHG%CHG
NAUT
Nautilus Biotechnology Inc
2.54-0.03-1.17%
BDTX
Black Diamond Therapeutics Inc
5.57-0.29-5.03%
TERN
Terns Pharmaceuticals Inc
5.05-0.05-0.98%
ATAI
ATAI Life Sciences NV
1.98+0.01+0.51%
ERAS
Erasca Inc
2.01-0.03-1.47%